Koers Celldex Therapeutics, Inc. Nasdaq
Aandelen
US15117B1035
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2,71 mln. 2,5 mln. | Omzet 2025 * | 2,66 mln. 2,45 mln. | Marktkapitalisatie | 2,49 mld. 2,29 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -153 mln. -141 mln. | Nettowinst (verlies) 2025 * | -196 mln. -180 mln. | EV/omzet 2024 * | 917 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 936 x |
K/w-verhouding 2024 * |
-16,3
x | K/w-verhouding 2025 * |
-13,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,66% |
Recentste transcriptie over Celldex Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Tibor Keler
FOU | Founder | 65 | 01-01-83 |
Anthony Marucci
FOU | Founder | 62 | 01-01-83 |
Sam Martin
DFI | Director of Finance/CFO | 53 | 01-04-09 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Herbert Conrad
BRD | Director/Board Member | 91 | 01-03-08 |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 16-06-22 |
Harry Penner
BRD | Director/Board Member | 78 | 01-01-97 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,79% | 54,04 mld. | |
+47,02% | 41,96 mld. | |
-0,56% | 41,92 mld. | |
-7,20% | 28,35 mld. | |
+12,59% | 26,35 mld. | |
-21,51% | 19 mld. | |
+6,92% | 13 mld. | |
+29,60% | 12,28 mld. | |
+24,91% | 12,19 mld. |